Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846854 | 0.84 | GABRA1 (0.35) | ALDH1A1GABRA1SLC6A4GABRB2HPGD | |
| SCHEMBL161859 | 0.80 | MAPK1 (0.47) | ALDH1A1GABRA1SLC6A4GABRB2HPGD | |
| SCHEMBL30785389 | 0.79 | ALDH1A1 (0.49) | ALDH1A1SLC6A4HPGDLMNACYP1A2 | |
| SCHEMBL191588 | 0.79 | ALDH1A1 (0.49) | ALDH1A1SLC6A4HPGDLMNACYP1A2 | |
| SCHEMBL1020285 | 0.79 | TP53 (0.42) | ALDH1A1SLC6A4HPGDCYP1A2TDP1 | |
| SCHEMBL15086587 | 0.78 | MAPK1 (0.34) | ALDH1A1GABRA1GABRB2HPGDLMNA | |
| SCHEMBL11415576 | 0.78 | TDP1 (0.44) | ALDH1A1GABRA1SLC6A4GABRB2HPGD | |
| SCHEMBL10967015 | 0.77 | APLNR (0.41) | ALDH1A1SLC6A4HPGDCYP1A2TDP1 | |
| SCHEMBL4191737 | 0.76 | MIF (0.34) | ALDH1A1SLC6A4HPGDCYP1A2TDP1 | |
| SCHEMBL15221620 | 0.76 | ALDH1A1 (0.33) | ALDH1A1SLC6A4HPGDLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399942-A1 | FLUORESCENT DYE OIL TRACER COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2023-12-14 | — | — | US | disclosed |
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | COSTALES ABRAN (US) | 2013-08-29 | — | — | US | disclosed |
| US-8519149-B2 | Tricyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519149-B2 | Tricyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519149-B2 | Tricyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| WO-2012055995-A1 | TRICYCLIC COMPOUNDS AS MPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012055995-A1 | TRICYCLIC COMPOUNDS AS MPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | disclosed |
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | disclosed |
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | disclosed |
| US-4134914-A | 1-Acyl-4-substituted phenyl thiosemicarbazides | ELI LILLY AND COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
| US-4082762-A | 4-(2-HALOPHENYL)-1,2,4-TRIAZOLE-3-THIOL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-3937713-A | Process for the preparation of s-triazolo[3,4-b]benzothiazoles | ELI LILLY AND COMPANY (US) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | PTGES, PTGS1, PTGIS | ALDH1A1 263/4885GABRA1 2659/4885SLC6A4 2100/4885 |
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | ALDH1A1 1397/4885GABRA1 1185/4885SLC6A4 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.